跳至主要内容
临床试验/EUCTR2006-001039-23-IT
EUCTR2006-001039-23-IT进行中(未招募)不适用

A Pilot Phase II Study for the evaluation of efficacy and tolerability of Gammaidroxybutyrate (ALCOVER) administered by oral route as add on treatmant in patients affected by DYT 11 Myoclonic Dystonia. - ND

ISTITUTO NEUROLOGICO CARLO BESTA0 个研究点开始时间: 2007年9月10日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Male and females > 17 years. Diagnosis of myoclonic dystonia genetically confirmed (mutation of epsilon sarcoglycan gene, 7q21-q31; DYT 11). Refractory to treatment with conventional medications. No contraindications to GHB. Written informed consent.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Serious medical and/or psychiatric diseases. More than two concomitant medications for myoclonic dystonia therapy and/or modifications of concomitant therapy in the last month prior to basal visit. Alcohol or drug abuse (last 2 years). Pregnant or lactating females. Subjects who received an experimantal drug or have participated in a clinical trial within 3 months prior to screening.

研究者

发起方
ISTITUTO NEUROLOGICO CARLO BESTA

相似试验